Drugs to Treat Systemic Lupus Erythematosus: Relationship between Current Use and Cardiovascular Risk Factors

Young Hee Rho, MD,* Annette Oeser, BS,* Cecilia P. Chung, MD, MPH,* Jason D. Morrow, MD,*† and C. Michael Stein, MD,*†

*Department of Medicine, †Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA

ABSTRACT

Objectives. Cardiovascular risk is increased in patients with systemic lupus erythematosus (SLE). Drugs used to treat SLE can modify traditional cardiovascular risk factors. We examined the effect of selected drugs used in the treatment of SLE on cardiovascular risk factors.

Methods. We compared systolic and diastolic blood pressure, serum lipid concentrations, glucose, homocysteine, and urinary F2-isoprostane concentrations in 99 patients with lupus who were either current users or non-users of systemic corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), COX-2 selective NSAIDs, azathioprine, and methotrexate. Multivariable adjustment was done with linear regression modeling using sex, age and disease activity (SLEDAI) as controlling variables.

Results. Serum triglyceride concentrations were higher (135.1 ± 61.4 vs. 95.3 ± 47.5 mg/dL, adjusted \( P = 0.003 \)) in patients receiving corticosteroids. Homocysteine concentrations were marginally higher in patients receiving methotrexate (adjusted \( P = 0.08 \)). Current use of either NSAIDs or COX-2 inhibitors was not associated with increased cardiovascular risk factors. Current hydroxychloroquine use was not associated with significant alterations in lipid profiles.

Conclusions. In a non-random sample of patients with SLE, current corticosteroid use was associated with increased triglyceride concentrations, but other drugs had little effect on traditional cardiovascular risk factors.

Key Words. Prednisone; Hydroxychloroquine; NSAID; COX-2 Inhibitor; Azathioprine, Methotrexate

Introduction

Patients with systemic lupus erythematosus (SLE) have accelerated atherosclerosis and increased cardiovascular morbidity and mortality [1]. We have found that cardiovascular risk factors such as triglyceride concentrations and the prevalence of hypertension were significantly higher in patients with SLE than controls [2]. Disease characteristics, or drugs used to treat the disease, could contribute to alterations in cardiovascular risk factors. Drugs used to treat SLE such as corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors can adversely affect cardiovascular risk factors such as blood pressure and lipid concentrations [3–5]. On the other hand, hydroxychloroquine has been reported to decrease total and LDL cholesterol and triglyceride concentrations [6]. We examined the hypothesis that current use of drugs used to treat SLE affects cardiovascular risk factors.

Methods

This study enrolled 99 patients with SLE from the Vanderbilt Lupus Cohort. This cohort had an increased prevalence of coronary atherosclerosis detected by electron-beam computed tomography...
Table 1  Descriptive data for the study group (N = 99)

| Factor                              | Mean ± SD | Mean ± SD |
|-------------------------------------|-----------|-----------|
| Age (years)                         | 40.2 ± 11.4 | 31.7 ± 8.4 |
| Sex (M/F)*                          | 8/91      | 61/39     |
| SLEDAI                              | 4.3 ± 4.0 | 4.3 ± 4.0 |
| SLICC                               | 0.79 ± 1.2 | 0.79 ± 1.2 |
| Systolic BP (mm Hg)                 | 139.6 ± 17.7 | 125.8 ± 21.0 |
| Diastolic BP (mm Hg)                | 73.8 ± 13.8 | 72.3 ± 12.5 |
| HDL cholesterol (mg/dL)             | 48.0 ± 14.8 | 47.3 ± 14.2 |
| LDL cholesterol (mg/dL)             | 105.4 ± 37.3 | 100.3 ± 31.1 |
| Triglycerides (mg/dL)               | 119.4 ± 59.4 | 113.2 ± 57.6 |
| Glucose (mg/dL)                     | 87.1 ± 27.0 | 85.3 ± 26.9 |
| Homocysteine (umol/L)               | 9.29 ± 2.78 | 9.93 ± 2.97 |
| F2 Isoprostane (ng/mg Creatinine)   | 2.84 ± 2.36 | 2.97 ± 2.87 |

*Shown as frequency.

SD = standard deviation; SLEDAI = systemic lupus erythematosus disease activity index; SLICC = systemic lupus international collaborating clinics group damage index; BP = blood pressure.

Cardiovascular risk factors were compared in patients receiving or not receiving a drug of interest (systemic corticosteroids, antimalarials, NSAIDs, COX-2 inhibitors, azathioprine, and methotrexate) using Mann-Whitney U tests. Additional multivariable adjustment was performed by linear regression using age, sex and SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) [12] as controlling variables. F2-isoprostane concentrations were logarithmic transformed for regression analysis. These analyses were exploratory, therefore no adjustment for multiple statistical comparisons were performed. Statistical analysis was conducted using SPSS 15.0 for Windows (SPSS Inc., Chicago, USA). Descriptive values are presented as mean ± standard deviation (SD). Statistical significance was determined as P < 0.05.

Results

Descriptive data for the SLE population are shown in Table 1. Cardiovascular risk factors in patients receiving or not receiving the drugs of interest are shown in Tables 2–7. As shown in Table 2, corticosteroids and current antimalarial use

| Factor                              | Corticosteroids (N = 60) | No corticosteroids (N = 39) | P      | P (Adjusted) |
|-------------------------------------|--------------------------|-----------------------------|--------|--------------|
| Systolic BP (mm Hg)                 | 121.7 ± 19.1             | 116.3 ± 15.0                | 0.14   | 0.40         |
| Diastolic BP (mm Hg)                | 75.8 ± 14.4              | 70.8 ± 12.6                 | 0.04   | 0.16         |
| HDL cholesterol (mg/dL)             | 48.9 ± 16.0              | 46.5 ± 12.8                 | 0.68   | 0.25         |
| LDL cholesterol (mg/dL)             | 108.9 ± 43.1             | 100.1 ± 25.6                | 0.31   | 0.41         |
| Triglycerides (mg/dL)               | 135.1 ± 61.4             | 95.3 ± 47.5                 | 0.001  | 0.003        |
| Glucose (mg/dL)                     | 88.6 ± 33.1              | 84.9 ± 13.1                 | 0.70   | 0.67         |
| Homocysteine (umol/L)               | 9.78 ± 2.98              | 8.55 ± 2.31                 | 0.05   | 0.11         |
| F2 Isoprostane (ng/mg Creatinine)   | 2.82 ± 2.31              | 2.87 ± 2.47                 | 0.88   | 0.96         |

P = unadjusted P values; P (adjusted) = adjusted for age, sex, and SLEDAI. Data are shown as mean ± SD.

| Factor                              | Antimalarials (N = 64) | No antimalarials (N = 35) | P      | P (Adjusted) |
|-------------------------------------|------------------------|---------------------------|--------|--------------|
| Systolic BP (mm Hg)                 | 118.7 ± 15.0           | 121.2 ± 22.0              | 0.97   | 0.59         |
| Diastolic BP (mm Hg)                | 73.3 ± 12.3            | 74.7 ± 16.4               | 0.75   | 0.68         |
| HDL cholesterol (mg/dL)             | 48.1 ± 13.2            | 47.7 ± 17.4               | 0.59   | 0.62         |
| LDL cholesterol (mg/dL)             | 108.2 ± 39.4           | 100.3 ± 33.1              | 0.69   | 0.23         |
| Triglycerides (mg/dL)               | 117.1 ± 63.2           | 123.6 ± 52.2              | 0.25   | 0.52         |
| Glucose (mg/dL)                     | 85.3 ± 19.3            | 90.4 ± 37.3               | 0.46   | 0.46         |
| Homocysteine (umol/L)               | 9.27 ± 2.70            | 9.33 ± 2.97               | 0.89   | 0.96         |
| F2 Isoprostane (ng/mg Creatinine)   | 2.66 ± 2.23            | 3.13 ± 2.56               | 0.48   | 0.46         |

P = unadjusted P values; P (adjusted) = adjusted for age, sex, and SLEDAI. Data are shown as mean ± SD.
teroid use was associated with increased serum triglycerides even after adjustment for age, sex, and disease activity (SLEDAI) \((P = 0.003)\). Antimalarial use was not associated with altered cardiovascular risk factors. Neither NSAIDs nor COX-2 inhibitors were associated with increased blood pressure or other risk factors. When patients taking (31 patients, 9 ACEI users) or not taking antihypertensive drugs were analyzed separately, blood pressure did not differ between non-NSAID and NSAID users (non-antihypertensive drug users: systolic 116.4 ± 13.4 mm Hg vs. 115.7 ± 13.8 mm Hg, diastolic 73.1 ± 8.3 vs. 79.7 ± 7.2 mm Hg).

### Table 4  Cardiovascular risk factors and current NSAID use

| Factor                        | NSAIDs (N = 22)       | No NSAIDs (N = 77) | \(P\)  | \(P\) (Adjusted) |
|-------------------------------|-----------------------|--------------------|--------|-----------------|
| Systolic BP (mm Hg)           | 118.8 ± 14.8          | 119.8 ± 18.5       | 0.87   | 0.85            |
| Diastolic BP (mm Hg)          | 71.1 ± 12.6           | 74.6 ± 14.2        | 0.39   | 0.42            |
| HDL cholesterol (mg/dL)       | 50.0 ± 16.6           | 47.4 ± 14.3        | 0.46   | 0.78            |
| LDL cholesterol (mg/dL)       | 107.4 ± 31.6          | 104.8 ± 39.0       | 0.37   | 0.72            |
| Triglycerides (mg/dL)         | 101.8 ± 47.6          | 124.4 ± 61.7       | 0.12   | 0.11            |
| Glucose (mg/dL)               | 89.3 ± 16.8           | 87.3 ± 29.3        | 0.68   | 0.71            |
| Homocysteine(umol/L)          | 9.10 ± 2.30           | 9.32 ± 2.92        | 0.81   | 0.88            |
| \(F_2\) Isoprostane (ng/mg Creatinine) | 3.10 ± 1.94         | 2.75 ± 2.49        | 0.13   | 0.23            |

\(P = \) unadjusted \(P\) values; \(P\) (adjusted) = adjusted for age, sex, and SLEDAI. Data are shown as mean ± SD.

### Table 5  Cardiovascular risk factors and current COX-2 inhibitor use

| Factor                        | COX-2 (N = 11)   | No COX-2 (N = 88) | \(P\)  | \(P\) (Adjusted) |
|-------------------------------|-----------------|-------------------|--------|-----------------|
| Systolic BP (mm Hg)           | 118.7 ± 15.3    | 120.0 ± 18.1      | 0.97   | 0.72            |
| Diastolic BP (mm Hg)          | 73.1 ± 9.3      | 73.9 ± 14.3       | 0.98   | 0.85            |
| HDL cholesterol (mg/dL)       | 51.9 ± 12.1     | 47.5 ± 15.0       | 0.23   | 0.39            |
| LDL cholesterol (mg/dL)       | 91.5 ± 25.6     | 107.1 ± 38.3      | 0.14   | 0.17            |
| Triglycerides (mg/dL)         | 83.5 ± 50.2     | 123.9 ± 59.1      | 0.01   | 0.021           |
| Glucose (mg/dL)               | 91.6 ± 21.7     | 86.6 ± 27.6       | 0.25   | 0.70            |
| Homocysteine(umol/L)          | 8.58 ± 2.37     | 9.38 ± 2.83       | 0.31   | 0.29            |
| \(F_2\) Isoprostane (ng/mg Creatinine) | 1.36 ± 0.71     | 2.98 ± 2.41       | 0.06   | 0.03            |

\(P = \) unadjusted \(P\) values; \(P\) (adjusted) = adjusted for age, sex, and SLEDAI. Data are shown as mean ± SD.

### Table 6  Cardiovascular risk factors and current azathioprine use

| Factor                        | Azathioprine (N = 10) | No Azathioprine (N = 89) | \(P\)  | \(P\) (Adjusted) |
|-------------------------------|-----------------------|--------------------------|--------|-----------------|
| Systolic BP (mm Hg)           | 117.9 ± 18.3          | 119.8 ± 17.7             | 0.83   | 0.53            |
| Diastolic BP (mm Hg)          | 66.7 ± 16.1           | 74.6 ± 13.4              | 0.16   | 0.034           |
| HDL cholesterol (mg/dL)       | 53.9 ± 15.0           | 47.3 ± 14.7              | 0.15   | 0.09            |
| LDL cholesterol (mg/dL)       | 89.3 ± 26.2           | 107.2 ± 38.0             | 0.09   | 0.09            |
| Triglycerides (mg/dL)         | 98.9 ± 39.7           | 121.7 ± 60.9             | 0.37   | 0.22            |
| Glucose (mg/dL)               | 84.3 ± 11.4           | 87.5 ± 28.2              | 0.81   | 0.77            |
| Homocysteine(umol/L)          | 9.62 ± 3.40           | 9.25 ± 2.72              | 0.90   | 0.90            |
| \(F_2\) Isoprostane (ng/mg Creatinine) | 3.38 ± 1.78         | 2.78 ± 2.42              | 0.21   | 0.16            |

\(P = \) unadjusted \(P\) values; \(P\) (adjusted) = adjusted for age, sex, and SLEDAI. Data are shown as mean ± SD.

### Table 7  Cardiovascular risk factors and current methotrexate (MTX) use

| Factor                        | MTX (N = 9)         | No MTX (N = 90)      | \(P\)  | \(P\) (Adjusted) |
|-------------------------------|---------------------|----------------------|--------|-----------------|
| Systolic BP (mm Hg)           | 133.4 ± 19.9        | 118.2 ± 17.0         | 0.01   | 0.047           |
| Diastolic BP (mm Hg)          | 79.7 ± 16.1         | 73.2 ± 13.5          | 0.16   | 0.33            |
| HDL cholesterol (mg/dL)       | 43.2 ± 13.9         | 48.4 ± 14.8          | 0.28   | 0.46            |
| LDL cholesterol (mg/dL)       | 123.2 ± 28.2        | 103.6 ± 37.8         | 0.06   | 0.23            |
| Triglycerides (mg/dL)         | 161.7 ± 56.2        | 115.2 ± 58.3         | 0.02   | 0.05            |
| Glucose (mg/dL)               | 88.1 ± 12.5         | 87.0 ± 28.1          | 0.25   | 0.96            |
| Homocysteine(umol/L)          | 11.22 ± 3.07        | 9.09 ± 2.69          | 0.03   | 0.08            |
| \(F_2\) Isoprostane (ng/mg Creatinine) | 3.11 ± 3.30        | 2.80 ± 2.24          | 0.87   | 0.85            |

\(P = \) unadjusted \(P\) values; \(P\) (adjusted) = adjusted for age, sex, and SLEDAI. Data are shown as mean ± SD.
\[ P = 0.85; \text{ diastolic } 72.5 \pm 10.7 \text{ mm Hg vs. } 70.9 \pm 12.5 \text{ mm Hg, } P = 0.68; \text{ anti-hypertensive users: systolic } 126.5 \pm 24.8 \text{ mm Hg vs. } 129.5 \pm 14.2 \text{ mm Hg, } P = 0.50; \text{ diastolic } 78.6 \pm 18.9 \text{ mm Hg vs. } 71.8 \pm 14.4 \text{ mm Hg, } P = 0.45. \]

COX-2 inhibitors were weakly associated with lower serum triglyceride concentrations and \( \text{F}_2\)-isoprostane excretion after statistical adjustment \((P = 0.02 \text{ and } P = 0.03, \text{ Table 5}). \) Methotrexate use was associated with higher serum homocysteine concentrations \((\text{unadjusted } P = 0.03 \text{ but this was attenuated after statistical adjustment } (P = 0.08, \text{ Table 7})\). Systolic blood pressure and triglyceride concentrations also tended to be higher in patients receiving methotrexate.

**Discussion**

The major finding of this study is that current exposure to drugs used to treat SLE is not a major contributor to the cardiovascular risk factors studied.

**Corticosteroids**

Systemic corticosteroids increase concentrations of triglycerides and blood pressure. Corticosteroids are thought to induce dyslipidemia through increased production of HDL, impaired catabolism of LDL, and increased lipoprotein lipase activity \([3]\). They also induce hypertension by increased systemic vascular resistance, extracellular volume, and cardiac contractility \([3]\). Corticosteroids are also known to induce glucose intolerance \([13]\). This study indicates that current corticosteroid use in patients with SLE is associated with higher triglyceride concentrations, but not with increased blood pressure or serum glucose concentrations. We have previously shown that cumulative exposure to corticosteroids was associated with higher triglyceride concentrations \([14]\).

**Antimalarials**

Use of antimalarials may decrease total and LDL cholesterol and triglyceride concentrations, and decreases the risk of thrombosis in patients with SLE \([6,15,16]\). In this study current antimalarial use was not associated with significant differences in lipid concentrations or cardiovascular risk factors. A potential explanation that should be considered is a type II error (i.e., lack of statistical power). However, based on previous data \([6]\) reporting that antimalarials decreased LDL concentrations by approximately 26 mg/dL, a post-hoc power analysis using PS \([17]\) showed that our sample size had approximately 93% power to detect an effect of similar magnitude. Thus, lack of statistical power is an unlikely explanation. We have previously reported that cumulative hydroxychloroquine use was not associated with lipid concentrations in this cohort of patients \([14]\).

**NSAIDs and COX-2 Inhibitors**

Traditional NSAIDs, and particularly COX-2 inhibitors, increase cardiovascular risk \([4,5]\). One mechanism by which NSAIDs and COX-2 inhibitors can increase cardiovascular risk is by increasing blood pressure. However, blood pressure did not differ among patients receiving NSAIDs or COX-2 inhibitors and those who did not. Triglyceride concentrations were lower in patients taking COX-2 inhibitors, but when additional statistical adjustment for corticosteroid use was performed, the association was no longer significant \((P = 0.08)\).

There is some experimental \([18,19]\) and clinical evidence \([20]\) that COX-2 inhibitors may be associated with a decrease in total cholesterol, LDL and triglyceride concentrations. Current use of COX-2 inhibitors was associated with lower \( \text{F}_2\)-isoprostane excretion, indicative of lower oxidative stress. Other studies have suggested that COX-2 selective drugs can decrease oxidative stress \([21,22]\).

**Methotrexate**

Methotrexate is widely used to treat rheumatoid arthritis and there are several reports indicating that it increases serum homocysteine concentrations due to folate antagonism \([23,24]\). Concomitant with those findings, this study showed an association between current use of methotrexate and increased serum homocysteine concentrations that was of marginal significance after adjustment for sex, age and SLEDAI. Since only 9 patients were receiving methotrexate, a larger sample would be required to further examine this observation. The modestly statistically significant differences in systolic blood pressure and triglycerides may be the result of the non-random design since these do not appear to be a feature of methotrexate therapy in large studies of patients with rheumatoid arthritis \([25,26]\).

**Limitations**

This study has several limitations. First, it was cross-sectional, and the pattern of drug use may have been affected by indication bias. Thus, patients with hypertension, for example, would be less likely to continue to receive drugs such as
NSAIDs. However, despite this limitation, the study provides valuable information about the relationship between current use of drugs and cardiovascular risk factors. For example, in this same cohort of patients, blood pressure was significantly higher than that of controls [2], however the findings of the current study suggest that this is not explained by current exposure to NSAIDs, COX-2 selective drugs, or corticosteroids. The second limitation is that drugs would be prescribed differentially according to SLE activity. We performed statistical adjustment for current disease activity using the SLEDAI score and therefore such bias may be reduced. Third, since the study was exploratory, we have performed multiple statistical comparisons without statistical adjustment and should be considered when interpreting the results. Nevertheless, since randomized controlled trials to examine the effects of the drugs of interest on cardiovascular risk factors in SLE are not feasible, the study provides useful information, despite its limitations.

Acknowledgments

Supported by NIH grants HL65082, GM5M01-RR00095. None of the authors has a conflict of interest related to this work.

Corresponding Author: Young Hee Rho, MD, Division of Clinical Pharmacology, Vanderbilt University, T-3207 MCN, Nashville, TN 37232, USA. Tel: (615) 322-4665; Fax: (615) 936-2746; E-mail: david.y.rho@vanderbilt.edu

Conflict of Interest: None declared.

References

1 Westerweel PE, Luyten RK, Koomans HA, Derksen RH, Verhaar MC. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 2007;56:1384–96.

2 Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, Linton MF, Raggi P, Stein CM. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2407–15.

3 Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 2000;16:505–11.

4 Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lansa A, Konstam MA, Baron JA. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092–102.

5 Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, T ang J, Rosenstei RB, Macdonald K, Bharda P, Fowler R, W ittes J, Zaub er AG, Solomon SD, Levin B. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885–95.

6 Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: Reversal of deleterious effects of steroids on lipids. Am J Med 1990;89:322–6.

7 Asanuma Y, Chung CP, Oeser A, Shintani A, Stanley E, Raggi P, Stein CM. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: Relationship to cardiovascular risk factors. J Rheumatol 2006;33:539–45.

8 Chung CP, Oeser A, Avalos I, Raggi P, Stein CM. Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus. Lupus 2006;15:562–9.

9 Chung CP, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P, Michael SC. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: Association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 2007;66:208–14.

10 Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.

11 Morrow JD. The isoprostanes—Unique products of arachidonate peroxidation: Their role as mediators of oxidant stress. Curr Pharm Des 2006;12:895–902.

12 Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630–40.

13 Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol 2001;33:289–94.

14 Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, Linton MF, Fazio S, Stein CM. Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus. J Rheumatol 2007;34:1849–54. [Epub 2007 Jul 15].

15 Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis. Am J Med 1994;96:254–9.

16 Ruiz-Irastorza G, Eguibide MV, Pijoan JI, Garnednia M, Villar I, Martinez-Berriotxoa A, Erdozain JG, Aguirre C. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006;15:77–83.
17 Dupont WD, Plummer WD. PS power and sample size program available for free on the Internet. Control Clin Trials 2007;18:274.

18 Kourounakis AP, Victoratos P, Peroulis N, Stefanou N, Yiagou M, Hadjipetrou L, Kourounakis PN. Experimental hyperlipidemia and the effect of NSAIDs. Exp Mol Pathol 2002;73:135–8.

19 Lu S, Archer MC. Celecoxib decreases fatty acid synthase expression via down-regulation of c-Jun N-terminal kinase-1. Exp Biol Med (Maywood) 2007;232:643–53.

20 Chow LW, Cheng CW, Wong JL, Toi M. Serum lipid profiles in patients receiving endocrine treatment for breast cancer—The results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial. Biomed Pharmacother 2005;59(suppl 2):S302–5.

21 Hermann M, Camici G, Fratton A, Hurlimann D, Tanner FC, Hellermann JP, Fiedler M, Thiery J, Neidhart M, Gay RE, Gay S, Luscher TF, Ruschitzka F. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 2003;108:2308–11.

22 Tomida T, Numaguchi Y, Nishimoto Y, Tsuzuki M, Hayashi Y, Imai H, Matsui H, Okumura K. Inhibition of COX-2 prevents hypertension and proteinuria associated with a decrease of 8-iso-PGF2alpha formation in L-NAME-treated rats. J Hypertens 2003;21:601–9.

23 Morgan SL, Baggott JE, Lee JY, Alarcon GS. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: Implications for cardiovascular disease prevention. J Rheumatol 1998;25:441–6.

24 van Ede AE, Laan RF, Blom HJ, Boers GH, Haagsma CJ, Thomas CM, De Boo TM, van de Putte LB. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford) 2002;41:658–65.

25 Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study. Lancet 2002;359:1173–7.

26 Georgiadis AN, Papavasiliou EC, Lourida ES, Alamanos Y, Kostara C, Telepis AD, Drosos AA. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: Effect of early treatment—A prospective, controlled study. Arthritis Res Ther 2006;8:R82.